These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1162 related articles for article (PubMed ID: 9622837)
1. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996]. Zäch K; Nicoara C; Germann D; Matter L Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837 [TBL] [Abstract][Full Text] [Related]
2. [Mumps epidemic in vaccinated children in West Switzerland]. Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835 [TBL] [Abstract][Full Text] [Related]
3. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. Chiu HH; Lee CY; Chih TW; Lee PI; Chang LY; Lin YJ; Hsu CM; Huang LM J Med Virol; 1997 Jan; 51(1):32-5. PubMed ID: 8986946 [TBL] [Abstract][Full Text] [Related]
4. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Matter L; Germann D; Bally F; Schopfer K Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781 [TBL] [Abstract][Full Text] [Related]
5. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96]. Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798 [TBL] [Abstract][Full Text] [Related]
6. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM; Saunders EF; Petric M; Gold R Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367 [TBL] [Abstract][Full Text] [Related]
7. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Just M; Berger R; Just V Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
10. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland. Narayan KM; Moffat MA Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895 [TBL] [Abstract][Full Text] [Related]
11. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection. Dennehy PH; Saracen CL; Peter G Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862 [TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus. Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112 [TBL] [Abstract][Full Text] [Related]
13. The combination measles, mumps, rubella and varicella vaccine in healthy children. Arbeter AM; Baker L; Starr SE; Plotkin SA Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of IgG-antibodies to mumps and measles virus in non-vaccinated children. Glikmann G; Petersen I; Mordhorst CH Dan Med Bull; 1988 Apr; 35(2):185-7. PubMed ID: 3359817 [TBL] [Abstract][Full Text] [Related]
15. [Changes in measles, mumps and rubella (MMR) immunity until the year of 2002 after the introduction of MMR vaccination]. Rønne T; Trier H Ugeskr Laeger; 1992 Jul; 154(29):2014-8. PubMed ID: 1509567 [TBL] [Abstract][Full Text] [Related]
16. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme. Tharmaphornpilas P; Yoocharean P; Rasdjarmrearnsook AO; Theamboonlers A; Poovorawan Y J Health Popul Nutr; 2009 Feb; 27(1):80-6. PubMed ID: 19248651 [TBL] [Abstract][Full Text] [Related]
17. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age. Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661 [TBL] [Abstract][Full Text] [Related]
18. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673 [TBL] [Abstract][Full Text] [Related]
19. Effect of simultaneous administration of live measles vaccine on the "take rate" of live mumps vaccine. André FE; Peetermans J Dev Biol Stand; 1986; 65():101-7. PubMed ID: 3556770 [TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immune response after measles vaccination in Taiwan. Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]